JP2016510989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510989A5 JP2016510989A5 JP2015562528A JP2015562528A JP2016510989A5 JP 2016510989 A5 JP2016510989 A5 JP 2016510989A5 JP 2015562528 A JP2015562528 A JP 2015562528A JP 2015562528 A JP2015562528 A JP 2015562528A JP 2016510989 A5 JP2016510989 A5 JP 2016510989A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- administration
- poxvirus
- nucleic acid
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 43
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 11
- 230000028993 immune response Effects 0.000 claims 11
- 108010028930 invariant chain Proteins 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 229960005486 vaccine Drugs 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 230000037452 priming Effects 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 241000700629 Orthopoxvirus Species 0.000 claims 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 208000007089 vaccinia Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000712891 Arenavirus Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 108091061960 Naked DNA Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000282576 Pan paniscus Species 0.000 claims 1
- 241000282577 Pan troglodytes Species 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940001442 combination vaccine Drugs 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000006461 physiological response Effects 0.000 claims 1
- 229940023867 prime-boost vaccine Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/055409 WO2014139587A1 (en) | 2013-03-15 | 2013-03-15 | Improved poxviral vaccines |
| EPPCT/EP2013/055409 | 2013-03-15 | ||
| PCT/IB2014/059802 WO2014141176A1 (en) | 2013-03-15 | 2014-03-14 | Improved poxviral vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510989A JP2016510989A (ja) | 2016-04-14 |
| JP2016510989A5 true JP2016510989A5 (enExample) | 2017-04-13 |
| JP6702725B2 JP6702725B2 (ja) | 2020-06-03 |
Family
ID=47882194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562528A Active JP6702725B2 (ja) | 2013-03-15 | 2014-03-14 | 改良されたポックスウイルスワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160000904A1 (enExample) |
| EP (1) | EP2968493B1 (enExample) |
| JP (1) | JP6702725B2 (enExample) |
| CN (2) | CN105307674A (enExample) |
| BE (1) | BE1021192B1 (enExample) |
| BR (1) | BR112015023524B1 (enExample) |
| CA (1) | CA2907026A1 (enExample) |
| CY (1) | CY1120740T1 (enExample) |
| DK (1) | DK2968493T3 (enExample) |
| ES (1) | ES2685922T3 (enExample) |
| HR (1) | HRP20181376T1 (enExample) |
| HU (1) | HUE040189T2 (enExample) |
| LT (1) | LT2968493T (enExample) |
| PL (1) | PL2968493T3 (enExample) |
| PT (1) | PT2968493T (enExample) |
| SI (1) | SI2968493T1 (enExample) |
| WO (2) | WO2014139587A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| US10576143B2 (en) | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| WO2017025782A1 (en) * | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
| DK3294326T3 (da) | 2015-05-15 | 2021-05-31 | Curevac Ag | Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion |
| CA3034124A1 (en) * | 2016-08-23 | 2018-03-01 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| MX2020000414A (es) * | 2017-07-12 | 2020-09-28 | Nouscom Ag | Composicion de vacuna de neoantigeno para el tratamiento del cancer. |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| GB201812647D0 (en) * | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| US20210283238A1 (en) | 2018-08-07 | 2021-09-16 | Glaxosmithkline Biologicals Sa | Novel processes and vaccines |
| EP3897846A1 (en) * | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
| US20220339281A1 (en) | 2019-03-05 | 2022-10-27 | GalxoSmithKline Biologicals SA | Hepatitis b immunisation regimen and compositions |
| CN111057716B (zh) * | 2019-07-27 | 2022-04-15 | 中国人民解放军军事科学院军事医学研究院 | 用于包装重组人4型腺病毒的单质粒载体系统及其应用 |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
| IT1278077B1 (it) | 1995-05-25 | 1997-11-17 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| JP4475561B2 (ja) | 2001-10-11 | 2010-06-09 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃ型肝炎ウイルスワクチン |
| EP2253709B1 (en) * | 2002-05-16 | 2018-04-11 | Bavarian Nordic A/S | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| ES2871907T3 (es) | 2004-01-23 | 2021-11-02 | Msd Italia Srl | Portadores de vacuna de adenovirus de chimpancé |
| PT1957528E (pt) | 2005-11-30 | 2013-01-09 | Univ Copenhagen | Uma vacina de nucleótido |
| BRPI0921927B8 (pt) * | 2008-11-21 | 2021-08-31 | Koebenhavns Univ University Of Copenhagen | Sensibilização de uma resposta imune |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| US10576143B2 (en) * | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| GB201321384D0 (en) | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| CA3034124A1 (en) | 2016-08-23 | 2018-03-01 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
-
2013
- 2013-03-15 WO PCT/EP2013/055409 patent/WO2014139587A1/en not_active Ceased
-
2014
- 2014-03-14 ES ES14723475.1T patent/ES2685922T3/es active Active
- 2014-03-14 PT PT14723475T patent/PT2968493T/pt unknown
- 2014-03-14 BR BR112015023524-7A patent/BR112015023524B1/pt active IP Right Grant
- 2014-03-14 CA CA2907026A patent/CA2907026A1/en active Pending
- 2014-03-14 DK DK14723475.1T patent/DK2968493T3/en active
- 2014-03-14 US US14/770,510 patent/US20160000904A1/en not_active Abandoned
- 2014-03-14 HR HRP20181376TT patent/HRP20181376T1/hr unknown
- 2014-03-14 CN CN201480015680.2A patent/CN105307674A/zh active Pending
- 2014-03-14 LT LTEP14723475.1T patent/LT2968493T/lt unknown
- 2014-03-14 BE BE2014/0166A patent/BE1021192B1/fr not_active IP Right Cessation
- 2014-03-14 PL PL14723475T patent/PL2968493T3/pl unknown
- 2014-03-14 HU HUE14723475A patent/HUE040189T2/hu unknown
- 2014-03-14 CN CN201811100700.2A patent/CN109182378A/zh active Pending
- 2014-03-14 EP EP14723475.1A patent/EP2968493B1/en active Active
- 2014-03-14 SI SI201430827T patent/SI2968493T1/sl unknown
- 2014-03-14 JP JP2015562528A patent/JP6702725B2/ja active Active
- 2014-03-14 WO PCT/IB2014/059802 patent/WO2014141176A1/en not_active Ceased
-
2017
- 2017-12-20 US US15/848,100 patent/US10588961B2/en active Active
-
2018
- 2018-08-14 CY CY181100859T patent/CY1120740T1/el unknown
-
2020
- 2020-02-05 US US16/782,268 patent/US11278614B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510989A5 (enExample) | ||
| ES2800623T3 (es) | Promotor PR13.5 para respuestas contundentes de células T y anticuerpos | |
| Verardi et al. | A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication | |
| Herbert et al. | Recombinant adenovirus expressing the haemagglutinin of peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR | |
| Gómez et al. | Clinical applications of attenuated MVA poxvirus strain | |
| EP1616954B1 (en) | Methods and reagents for vaccination which generate a CD8+ Tcell immune response against hepatitis B or C | |
| Schneider et al. | Induction of CD8+ T cells using heterologous prime‐boost immunisation strategies | |
| MX2022009962A (es) | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. | |
| JP2014503206A5 (enExample) | ||
| JP2015533841A5 (enExample) | ||
| AU2002347317B2 (en) | Vaccine | |
| US20160304582A1 (en) | Molecular adjuvant | |
| SG10201901735XA (en) | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| CA3067405A1 (en) | Personalized vaccine comprising a recombinant poxvirus expressing a fusioin of nepopeptides | |
| RU2019107976A (ru) | Композиция вакцины | |
| JP6851364B2 (ja) | ポックスウイルスにおける発現を増強するためのプロモーター | |
| JP2016510989A (ja) | 改良されたポックスウイルスワクチン | |
| JP2012515557A5 (enExample) | ||
| ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
| JP2017527568A (ja) | フィロウイルス感染に対する防御免疫の誘導を目的とする方法及び組成物 | |
| JP2017503479A (ja) | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター | |
| JP2018521651A5 (enExample) | ||
| JP2010523138A5 (enExample) | ||
| JP2019528271A5 (enExample) |